A new FDA ruling could impact the lives of many heart patients in our area and around the country.
Prior to last week, the Transcatheter Aortic Valve Implantation, or the TAVR, was only available as an option for patients with a high risk of death or severe complications.
However, the FDA ruled Friday that the device, which widens the aortic valve and allows greater blood flow to the aorta, will now be available to low-risk patients, as well.
Before last week’s ruling, low-risk patients would have to go through invasive surgeries.
Dr. Jeremiah Depta of Rochester General Hospital says this will open doors for many heart patients.